Search
Abemaciclib
go.drugbank.com/drugs/DB12001ApprovedInvestigationalAbemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA gr...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesNirogacestat
go.drugbank.com/drugs/DB12005ApprovedInvestigationalNirogacestat is a small-molecule gamma-secretase inhibitor that was investigated as a potential treatment for desmoid tumors. Desmoid tumors are typically characterized by aberrant activation in Notch signaling. Interaction between the n...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesVoxilaprevir
go.drugbank.com/drugs/DB12026ApprovedInvestigationalVoxilaprevir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSarecycline
go.drugbank.com/drugs/DB12035ApprovedInvestigationalSarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II ...
Categories: P-glycoprotein inhibitorsMafosfamide
go.drugbank.com/drugs/DB12083InvestigationalMafosfamide has been used in trials studying the treatment of Lymphoma, Leukemia, Meningeal Neoplasm, and Brain and Central Nervous System Tumors.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsTetrahydropalmatine
go.drugbank.com/drugs/DB12093InvestigationalTetrahydropalmatine is under investigation in clinical trial NCT02118610 (Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesIberdomide
go.drugbank.com/drugs/DB12101InvestigationalIberdomide is an orally administered cereblon-modulating protein degrader (CELMoD) used to treat multiple myeloma. It binds cereblon, the substrate-recognition component of an E3 ubiquitin ligase complex, and drives the ubiquitination an...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesErdafitinib
go.drugbank.com/drugs/DB12147ApprovedInvestigationalIn early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or m...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesBrincidofovir
go.drugbank.com/drugs/DB12151ApprovedInvestigationalBrincidofovir is an oral antiviral drug used in the treatment of human smallpox infections. It is a lipid conjugate pro-drug of the acyclic nucleotide analogue cidofovir - this lipid conjugate improves drug delivery to the target cells a...
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2B6 InhibitorsDeutetrabenazine
go.drugbank.com/drugs/DB12161ApprovedInvestigationalDeutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a d...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates